Lincoln Pharmaceuticals (531633) Q4 98/99 earnings summary

Executive summary

• FY1998-99 sales reached Rs 2,533.95 lacs versus Rs 1,840.08 lacs; net profit rose to Rs 138.24 lacs from Rs 125.32 lacs.

• Directors recommended a 12% dividend for the year ended 31 March 1999.

Financial highlights

• Profit before tax was Rs 167.82 lacs versus Rs 148.32 lacs; tax provision was Rs 25.00 lacs, plus Rs 4.58 lacs for an earlier-year income-tax short provision.

• Other income was Rs 96.37 lacs versus Rs 93.15 lacs; stock variation added Rs 95.29 lacs versus Rs 53.62 lacs.

• Raw-material consumption rose to Rs 995.98 lacs from Rs 562.38 lacs; manufacturing expenses were Rs 557.66 lacs versus Rs 342.69 lacs.

• Export sales were Rs 598.10 lacs versus Rs 363.79 lacs; domestic sales were Rs 1,935.84 lacs versus Rs 1,476.30 lacs.

Segment performance

• Lindane production was 54,000 litres and sales were Rs 71.99 lacs; D-cold syrup production was 2,237,824 bottles and sales were Rs 197.78 lacs.

• Primaquine production reached 60 million tablets versus 360,000; sales were Rs 107.40 lacs versus Rs 0.90 lacs.

• Other products generated sales of Rs 2,156.78 lacs versus Rs 1,839.18 lacs.